Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Open-label Single Arm Study Of The Efficacy And Safety Of Pf-02341066 In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus

Next Previous
Trial Profile

Phase 2, Open-label Single Arm Study Of The Efficacy And Safety Of Pf-02341066 In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms P1005; PROFILE-1005
  • Sponsors Pfizer

    • Most Recent Events

    • 09 Jun 2019 Planned number of patients changed from 1069 to 1100.
    • 26 Feb 2019 Results of pooled analysis (data cutoff date 15 July 2014) of four clinical trials (NCT00585195,NCT00932451,NCT00932893 and NCT01154140) evaluating renal effects of crizotinib in patients with advanced Non-Small Cell Lung Cancer published in the Journal of Thoracic Oncology
    • 13 Jul 2018 Results assessing Crizotinib efficacy in three prospective studies ((PROFILE 1005, PROFILE 1007, and PROFILE 1014), were published in the Annals of Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top